Society guideline links: Screening for ovarian cancer

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately. (See "Society guideline links: Ovarian and fallopian tube disease".)

Canada

●Choosing Wisely Canada: Don't screen for ovarian cancer in asymptomatic women at average risk (2021)

United States

●National Cancer Institute (NCI): PDQ ovarian, fallopian tube, and primary peritoneal cancer screening – Health professional version (2022)

●American College of Obstetricians and Gynecologists (ACOG) and Society of Gynecologic Oncology (SGO): Committee opinion on the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer in women at average risk (2017, reaffirmed 2021)

●ACOG: Committee opinion on hereditary cancer syndromes and risk assessment (2019)

●US Preventive Services Task Force (USPSTF): Final recommendation statement on ovarian cancer – Screening (2018)

●ACOG: Practice bulletin No. 182 – Hereditary breast and ovarian cancer syndrome (2017)

●ACR: Appropriateness Criteria on ovarian cancer screening (2017)

Europe

●European Society for Medical Oncology (ESMO): Clinical practice guidelines for prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes (2016)